Systemic chemotherapy trial for extraocular retinoblastoma

A multi-centric, multi-arm, superiority, randomized controlled trial of systemic chemotherapy for non-metastatic, extraocular retinoblastoma (MaSTER-Retinoblastoma study) - MaSTER-Retinoblastoma study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/083895

Enrollment

350

Registered

2025-04-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H36- Retinal disorders in diseases classified elsewhere

Interventions

Intervention1: higher dose VEC chemotherapy regimen: 12 cycles of higher dose carboplatin containing VEC regimen (Vincristine, Etoposide, Carboplatin) Intervention2: Alternating VDC and VEC: 8 Cycles

Eligibility

Inclusion criteria

Inclusion criteria: Children with newly diagnosed extraocular retinoblastoma 1. Age 1- 18 years old 2. Extraocular retinoblastoma 3. IRSS Stages II & III 4. Unilateral or extraocular

Exclusion criteria

Exclusion criteria: 1. Metastatic disease at diagnosis (IRSS Stage IV) 2. Any prior chemotherapy or Radiotherapy 3. Refusal to consent

Design outcomes

Primary

Measure	Time frame
Event free survival (EFS)Timepoint: 3 YEARS	—

Secondary

Measure	Time frame
Overall survival, disease free survival, treatment related adverse effects Timepoint: 3 years	—

Countries

India

Contacts

Public ContactSrinivasan PP

Postgraduate Institute of Medical Education and Research, Chandigarh

psrinivasan225@gmail.com8437249895

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026